ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
H2APEX Group SCA

H2APEX Group SCA (H2A)

2.88
0.08
(2.86%)
Cerrado 23 Marzo 3:00PM
Realtime Data
Gráfico avanzado
Rendering Error

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
2.88
Postura de Compra
2.80
Postura de Venta
2.96
Volume Operado de la Acción
5,242
2.66 Rango del Día 2.96
2.66 Rango de 52 semanas 7.15
Capitalización de Mercado [m]
Precio Anterior
2.80
Precio de Apertura
2.94
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
2,878
Acciones en circulación
20,073,696
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
0.00
Beneficio por acción (BPA)
-
turnover
17.61M
Beneficio neto
-24.69M

Acerca de H2APEX Group SCA

Sector
Finance Services
Industria
Finance Services
Sitio web
Sede
Grevenmacher, Grevenmacher, Lux
Fundado
-
H2APEX Group SCA is listed in the Finance Services sector of the Tradegate (DE) with ticker H2A. The last closing price for H2APEX Group SCA was 2.80 €. Over the last year, H2APEX Group SCA shares have traded in a share price range of 2.66 € to 7.15 €.

H2APEX Group SCA currently has 20,073,696 shares in issue. The market capitalisation of H2APEX Group SCA is 56.21 € million.

H2A Últimas noticias

No hay noticias para mostrar aún.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.74-20.44198895033.623.622.6690773.04126911DE
4-1.32-31.42857142864.24.82.6653873.53805853DE
12-2.67-48.10810810815.556.752.6628783.96140867DE
26-1.7199999-37.39130298684.59999996.752.6623864.53521463DE
52-3.42-54.28571428576.37.152.6617664.7789378DE
156-2.97-50.76923076925.857.852.6616924.8758204DE
260-2.97-50.76923076925.857.852.6616924.8758204DE

H2A - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de H2APEX Group SCA?
El precio actual de las acciones de H2APEX Group SCA es 2.88 €
¿Cuántas acciones de H2APEX Group SCA están en circulación?
H2APEX Group SCA tiene 20,073,696 acciones en circulación
¿Cuál es la capitalización de mercado de H2APEX Group SCA?
La capitalización de mercado de H2APEX Group SCA es EUR 56.21M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de H2APEX Group SCA?
H2APEX Group SCA ha negociado en un rango de 2.66 € a 7.15 € durante el último año
¿Cuál es la moneda de reporte de H2APEX Group SCA?
H2APEX Group SCA presenta sus resultados financieros en EUR
¿Cuál es el último ingresos anual de H2APEX Group SCA?
El último ingresos anual de H2APEX Group SCA es EUR 17.61M
¿Cuál es el último beneficio anual de H2APEX Group SCA?
El último beneficio anual de H2APEX Group SCA es EUR -24.69M
¿Cuál es la dirección registrada de H2APEX Group SCA?
La dirección registrada de H2APEX Group SCA es 19, RUE DE FLAXWEILER, GREVENMACHER, GREVENMACHER, L-6776
¿Cuál es la dirección del sitio web de H2APEX Group SCA?
La dirección del sitio web de H2APEX Group SCA es www.h2apex.com
¿En qué sector industrial opera H2APEX Group SCA?
H2APEX Group SCA opera en el sector FINANCE SERVICES

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
AMIMedondo Holding AG
0.498 €
(91.54%)
180
R1EAEV Resources Ltd
0.0036 €
(63.64%)
70k
GTYGateway Real Estate AG
0.65 €
(44.44%)
13.3k
51JVivoPower International PLC
1.14 €
(43.40%)
29.04k
9YZCredissential Inc
0.019 €
(31.03%)
19.5k
E3O1Nexoptic Technology Corp
0.006 €
(-29.41%)
1.99k
PA8Paion AG
0.0142 €
(-28.28%)
75
PNYPine Technology Holdings Ltd
0.004 €
(-27.27%)
20k
L7C2Windfall Geotek Inc
0.0085 €
(-26.09%)
71.58k
GAG0GORE German Office Real Estate AG
0.10 €
(-25.93%)
4k
DEZDeutz AG
7.33 €
(19.19%)
4.37M
D7GNel ASA
0.2585 €
(-1.11%)
3.29M
DMLSayona Mining Limited
0.0119 €
(-4.03%)
2.72M
LLDLloyds Banking Group PLC
0.86 €
(-2.27%)
2.23M
0QJHexagon Purus ASA
0.1296 €
(-17.66%)
1.84M

H2A Finanzas

Finanzas
Rendering Error
$2.00 or no deal $2.00 or no deal 4 minutos hace
Nice...

Repeal the Mikah Tax -- To be paid by all shareholders at buyout
1. Cost of Second Tier Suitors
2. Cost of Secret Side Deal with Hakim
3. Cost of Mikah litigation
4. Cost of remaining OTC
ELTP
$2.00 or no deal $2.00 or no deal 4 minutos hace
All the BE studies failed last year.

Nasrat lied to us when said QUOTE "At least two ANDA's will be filed in 2024".

And he said one of these was the CNS product (Concerta).

I’d like Elite to expand their portfolio. The best way is having ANDA’s approved.
ELTP
$2.00 or no deal $2.00 or no deal 8 minutos hace
You mean Kirko...

Nasrat was all in years ago and deserves both the credit and the rewards for making this company a force in the generic drug field.
ELTP
Truenorth2016 Truenorth2016 15 minutos hace
Also Stervc, GCAN CEO Aitan keeps emphasizing in Core Gaming Pr's and the merger video, this:

"Core Gaming has developed cutting edge AI tools using text, language, image and video models to achieve a 50% boost in content production, reducing production time by over 40%, and significa
GCAN
Peter J Peter J 17 minutos hace
Well...HELLO mr fung derf...

LET'S WELCOME A NEW MEMBER TO THE ALTRUIST GANG... 🤣

However, my answer is, I don't care about what is posted if its not intended to hurt others
ERHE
Polymer Paul Polymer Paul 17 minutos hace
This is good.... So you now know that when Yves says 18-24 months for results... He means 18-24 months !!! Long time off that Belgium ... Very long time in the stock world. Good luck with that
LWLG
$2.00 or no deal $2.00 or no deal 18 minutos hace
EVERYONE CARES about what happened 10 years ago!

NO ONE CARES about what happened 10 years ago!
ELTP
$2.00 or no deal $2.00 or no deal 19 minutos hace
Agreed!

Hakim is a miserable failure when it comes to fulfilling his fiduciary duty to Elite shareholders.
ELTP
Peter J Peter J 19 minutos hace
Still posting, mr. 6503 posts? While having no financial interest here... 🤣
https://investorshub.advfn.com/boards/profileb.aspx?user=44043
ERHE
$2.00 or no deal $2.00 or no deal 20 minutos hace
He's been horrible.

Nasrat has been an amazing CEO for investors that have held their shares.
ELTP
Wayne R Wayne R 21 minutos hace
Last month was last month, this is this month and they just voted for another this month.

Sure, I know it is hard to keep track....
MULN
BDEZ BDEZ 30 minutos hace
LBJ Talks About Shooting Methamphetamine with Jackie Kennedy in Newly Released Presidential Phone Call

https://x.com/RealAlexJones/status/1903544281098330461
Truenorth2016 Truenorth2016 33 minutos hace
In Our Face Stervc!! NVDA and Core Gaming has the same tech and this is why GCAN CEO Aitan Zacharin keep saying his company is going to soon be the Number One "AI Gaming" Company in the world...... AITAN has something up his sleeve.....he knows he has tech that no one else has or has an edge on othe
GCAN NVDA
SkeBallLarry SkeBallLarry 33 minutos hace
Now there's a good one, Trin .. !!!
Investor2014 Investor2014 36 minutos hace
In the current context and considering Missling is from Europe, where approval is sought from EMA. Anavex have run only one tiny adult Rett trial in the U.S., all other trials have been run in countries collaborating with Europe. Considering all this - the Anavex HQ may not be in NYC or anywhere clo
AVXL
BDEZ BDEZ 43 minutos hace
Foreman was a prominent promoter of the jab. Even doing paid commercials

https://x.com/RealAlexJones/status/1903397708368404556
Flexplate Flexplate 48 minutos hace
Live Update At 09:18:06 EST: On Friday, March 21, 2025 TransCode Therapeutics Inc. stock [NASDAQ: RNAZ] is trending up by 34.42%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

TransCode Therapeutics received a nod to proc
RNAZ
cleanerworldwehope cleanerworldwehope 52 minutos hace
Scancell announces further positive data from the ongoing SCOPE trial of SCIB1 with double CPIs for Advanced
Melanoma
80% Progression Free Survival in 25 patients at 6 months
20% (5) patients have shown a complete response following treatment
Disease Control Rate of 84% a
MRNA
janice shell janice shell 53 minutos hace
I think perhaps he should report it to his carrier as phishing. That might make it go away. At least for a while.
Flexplate Flexplate 53 minutos hace
The amount of bullish sentiment on this is insane. One of the other chat pages I'm on has gained over 900 new followers on RNAZ since Fridays close. Monday this is going to run hard!
RNAZ
Investor2014 Investor2014 56 minutos hace
You misunderstood Hoskuld’s sentence, go back, read and think.
AVXL
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 56 minutos hace
I want this stock to go UP. It just never does.

But you said it went up 31 cents this week!

please explain
AVXL
cleanerworldwehope cleanerworldwehope 57 minutos hace
Moderna/Merck’s Phase 3 trial (V940-001, NCT05933577) is expected to enroll ~1,089 patients
SCNLF

Su Consulta Reciente

Delayed Upgrade Clock